Literature DB >> 34218991

Black clients in expansion states who used opioids were more likely to access medication for opioid use disorder after ACA implementation.

Natrina L Johnson1, Sugy Choi2, Carolina-Nicole Herrera3.   

Abstract

INTRODUCTION: Black people in the United States who use opioids receive less treatment and die from overdoses at higher rates than White people. Medication for opioid use disorder (MOUD) decreases overdose risk. Implementation of the Affordable Care Act (ACA) in the United States was associated with an increase in MOUD. To what extent racial disparity exists in MOUD following ACA implementation remains unclear. Using a national sample of people seeking treatment for opioids (clients), we compared changes in MOUD after the ACA to determine whether implementation was associated with increased MOUD for Black clients relative to White clients.
METHODS: We identified 878,110 first episodes for clients with opioids as primary concern from SAMHDA's Treatment Episodes Dataset-Admissions (TEDS-A; 2007-2018). We performed descriptive and logistic regression analyses to estimate odds of MOUD for Black and White clients by Medicaid expansion status. We interacted ACA implementation with racial group and performed subpopulation analyses for Medicaid enrollees and criminal justice-referred clients.
RESULTS: In expansion states post-ACA, MOUD increased from 33.6% to 51.3% for White clients and from 36.2% to 61.7% for Black clients. Pre-ACA, Black clients were less likely than White clients to use MOUD (adjusted odds ratio (aOR) = 0.88, 99th Confidence Interval (CI) = [0.85, 0.91]), and post-ACA, the change in odds of MOUD did not differ. Criminal justice-referred clients experienced less of a change in odds of MOUD among Black clients than among White clients (aOR = 0.74, CI = [0.62, 0.89]). Among Medicaid-insured clients, the change in odds of MOUD among Black clients was larger (aOR = 1.16, CI = [1.03, 1.30]). In the non-expansion states before 2014, Black clients were less likely to receive MOUD (aOR = 0.86, CI = [0.77, 0.95]) than White clients. After 2014, the change in odds of MOUD increased more for Black clients relative to White clients (aOR = 1.24, CI = [1.07, 1.44]). We did not find significant changes in MOUD for clients referred through the criminal justice system or with Medicaid.
CONCLUSION: The ACA was associated with increased use of MOUD among Black clients and reduction in treatment disparity between Black and White clients. For criminal justice-referred Black clients, disparities in MOUD persist. Black clients with Medicaid in expansion states had the greatest reduction in disparities.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Medicaid expansion; Medication for addiction treatment (MAT); Policy evaluation; Race; Substance use disorder (SUD)

Mesh:

Substances:

Year:  2021        PMID: 34218991      PMCID: PMC8664894          DOI: 10.1016/j.jsat.2021.108533

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  47 in total

1.  The Surge of Opioid Use, Addiction, and Overdoses: Responsibility and Response of the US Health Care System.

Authors:  Bertha K Madras
Journal:  JAMA Psychiatry       Date:  2017-05-01       Impact factor: 21.596

2.  The Effect of Public Insurance Expansions on Substance Use Disorder Treatment: Evidence from the Affordable Care Act.

Authors:  Johanna Catherine Maclean; Brendan Saloner
Journal:  J Policy Anal Manage       Date:  2019

3.  Medication-assisted therapies--tackling the opioid-overdose epidemic.

Authors:  Nora D Volkow; Thomas R Frieden; Pamela S Hyde; Stephen S Cha
Journal:  N Engl J Med       Date:  2014-04-23       Impact factor: 91.245

4.  Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.

Authors:  Sarah E Wakeman; Marc R Larochelle; Omid Ameli; Christine E Chaisson; Jeffrey Thomas McPheeters; William H Crown; Francisca Azocar; Darshak M Sanghavi
Journal:  JAMA Netw Open       Date:  2020-02-05

5.  Impact of Medicaid Expansion on Medicaid-covered Utilization of Buprenorphine for Opioid Use Disorder Treatment.

Authors:  Hefei Wen; Jason M Hockenberry; Tyrone F Borders; Benjamin G Druss
Journal:  Med Care       Date:  2017-04       Impact factor: 2.983

6.  Opioid use disorder in primary care: PEER umbrella systematic review of systematic reviews.

Authors:  Christina Korownyk; Danielle Perry; Joey Ton; Michael R Kolber; Scott Garrison; Betsy Thomas; G Michael Allan; Nicolas Dugré; Caitlin R Finley; Rhonda Ting; Peter Ran Yang; Ben Vandermeer; Adrienne J Lindblad
Journal:  Can Fam Physician       Date:  2019-05       Impact factor: 3.275

7.  Increasing deaths from opioid analgesics in the United States.

Authors:  Leonard J Paulozzi; Daniel S Budnitz; Yongli Xi
Journal:  Pharmacoepidemiol Drug Saf       Date:  2006-09       Impact factor: 2.890

8.  African Americans now outpace whites in opioid-involved overdose deaths: a comparison of temporal trends from 1999 to 2018.

Authors:  Debra Furr-Holden; Adam J Milam; Ling Wang; Richard Sadler
Journal:  Addiction       Date:  2020-09-15       Impact factor: 6.526

9.  Private Coverage of Methadone in Outpatient Treatment Programs.

Authors:  Daniel Polsky; Samantha Arsenault; Francisca Azocar
Journal:  Psychiatr Serv       Date:  2019-12-11       Impact factor: 3.084

10.  Medicaid Expansion Increased Medications For Opioid Use Disorder Among Adults Referred By Criminal Justice Agencies.

Authors:  Utsha G Khatri; Benjamin A Howell; Tyler N A Winkelman
Journal:  Health Aff (Millwood)       Date:  2021-04       Impact factor: 6.301

View more
  2 in total

1.  Estimating the impact on initiating medications for opioid use disorder of state policies expanding Medicaid and prohibiting substance use during pregnancy.

Authors:  Sugy Choi; Michael D Stein; Julia Raifman; David Rosenbloom; Jack A Clark
Journal:  Drug Alcohol Depend       Date:  2021-10-29       Impact factor: 4.492

Review 2.  Did Medicaid expansion close African American-white health care disparities nationwide? A scoping review.

Authors:  Lonnie R Snowden; Genevieve Graaf; Latocia Keyes; Katherine Kitchens; Amanda Ryan; Neal Wallace
Journal:  BMC Public Health       Date:  2022-08-30       Impact factor: 4.135

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.